VANCOUVER, Dec. 24,
2015 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the
Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced the
appointment of Susan Koppy and
John Meekison to iCo's Board of
Directors.
Ms. Koppy has more than 30 years of experience in
marketing and business development in the bio-pharmaceutical
industry in the U.S., Europe, and
Japan. She has participated in the negotiation of numerous
agreements with a multi-billion dollar aggregate commercial value
and is a frequent speaker on business development issues in the
industry. After 15 years working through progressive
positions of responsibility in life sciences, Ms. Koppy joined
Novartis Pharmaceuticals AG in Basel
Switzerland in 2000 where she became the first woman on the
global marketing management team. Between 2005 and 2008 she
built and led strategy, business development and acquisition groups
for Applied Biosystems, Inc., Idenix Pharmaceuticals and Transcept
Pharmaceuticals where she successfully sourced and executed a major
U.S. partnership with Purdue Pharmaceuticals. Ms. Koppy now
consults with a variety of bio-pharmaceutical companies on business
development strategy, search, and transactions in a broad variety
of therapeutic areas both in- and out-licensing. She is a
member of the National Association for Corporate Directors,
Healthcare Businesswomen's Association, and Licensing Executive
Society.
Mr. Meekison, CPA, CMA, P.Log., CIM is a
co-founder and has been CFO of iCo Therapeutics Inc. since February
2005. He is a former investment banker having worked at a
number of investment firms including: Loewen Ondaatje
McCutcheon; Haywood Securities; Dlouhy Merchant Group; and PI
Financial Corp. As a financier, Mr. Meekison has raised
equity capital for technology and biotechnology companies both in
Canada and the United
States. Mr. Meekison's areas of expertise include:
financial/treasury management, risk management, capital formation,
corporate governance, mergers and acquisitions and business
strategy. Mr. Meekison sits on the Board of Directors
of Sojourn Ventures Inc. and Natcore Technology Inc. Mr.
Meekison is a Chartered Professional Accountant, a Certified
Investment Manager and Professional Logistician. He received
his BA from the University of British
Columbia.
As Ms. Koppy and Mr. Meekison join the Board of
Directors, Doug Janzen and
Noel Hall will step down, effective
immediately. Mr. Janzen and Mr. Hall are thanked by the board and
management for their service.
About iCo Therapeutics
iCo
Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for
new or expanded use indications. The Company holds worldwide rights
to an oral drug delivery platform, with Oral Amphotericin B (Amp B)
as the initial platform candidate, utilizing a known anti-fungal
drug to treat life-threatening infectious diseases. iCo also
has worldwide rights to two drug candidates: iCo-007 is a second
generation antisense drug candidate targeting C-Raf kinase and
iCo-008 is a monoclonal antibody targeting eotaxin-1. With
Phase 2 clinical history, Bertilimumab (iCo-008) is a candidate for
the treatment of vernal or atopic keratoconjunctivitis and wet
age-related macular degeneration. iCo-008 is in Phase 2
clinical studies with iCo's partner, Immune Pharmaceuticals. iCo
trades on the TSX Venture Exchange under the symbol "ICO" and the
OTCQX under the symbol "ICOTF". For more information, visit the
Company website at: www.icotherapeutics.com.
No regulatory authority has approved or
disapproved the content of this press release. Neither the TSX
Venture Exchange nor its Regulatory Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this press
release.
Forward Looking Statements
Certain
statements included in this press release may be considered
forward-looking statements" within the meaning of applicable
securities laws. Forward-looking statements can be identified
by words such as: "anticipate," "intend," "plan," "goal," "seek,"
"believe," "project," "estimate," "expect," "strategy," "future,"
"likely," "may," "should," "will," and similar references to future
periods. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should
not be read as guarantees of future performance or results. All
forward-looking statements are based on iCo's current beliefs as
well as assumptions made by and information currently available to
iCo and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are based only on information currently available
to iCo and speak only as of the date of this press release. Due to
risks and uncertainties, including the risks and uncertainties
identified by iCo in its public securities filings and on its
website, actual events may differ materially from current
expectations. iCo disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, except as required by
law.
SOURCE iCo Therapeutics Inc.